Lynch Thomas P. 4
4 · Orexigen Therapeutics, Inc. · Filed Oct 17, 2017
Insider Transaction Report
Form 4
Lynch Thomas P.
EVP. General Counsel & Sec.
Transactions
- Award
Restricted Stock Unit (RSU)
2017-10-13+69,600→ 69,600 total→ Common Stock (69,600 underlying)
Footnotes (3)
- [F1]Each RSU represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.
- [F2]Reflects an award of restricted stock units ("RSUs"), each representing a contingent right to receive a share of the issuer's common stock upon settlement.
- [F3]Twenty-five percent (25%) of the RSUs will vest on each of the first four (4) anniversaries of February 3, 2018 (each, a "Vesting Date"), subject to the reporting person's continued eligibility on each applicable Vesting Date.